# SonoVascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sonovascular

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.sonovascular.com
- Total disclosed funding: $6M
- Latest round: Series A (Feb 3, 2026)
- Investors on record: 1

## About

SonoVascular, Inc. is a US-based medical device company specializing in innovative interventional solutions for venous thromboembolism, including advanced systems for thrombectomy procedures.Founded in 2021, SonoVascular, Inc. focuses on developing advanced medical devices for vascular care. The company is led by Daniel Estay, who also serves as the CEO. SonoVascular raised USD 6.000 mn in Series A funding on February 3, 2026, with Harbright Ventures as the lead investor. This funding supports the company's growth in developing treatments for pulmonary embolism.SonoVascular's primary offering is the SonoThrombectomy™ system, designed for treating venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). This system employs a Triple Action Clot Debulking Catheter driven by microbubble-mediated cavitation, allowing for a single-session treatment in catheterization labs without ICU monitoring. The main customers include healthcare facilities such as hospitals and specialized clinics focused on cardiovascular care in the United States.SonoVascular generates revenue by selling its proprietary medical devices, particularly the SonoThrombectomy™ system, to healthcare institutions. The sales operate on a B2B basis, where hospitals purchase equipment and consumables for their cardiovascular departments. The business model encompasses one-time equipment sales alongside recurring revenue from the ongoing sale of necessary consumables for the procedures.In February 2026, SonoVascular, Inc. secured USD 6.000 mn in Series A funding led by Harbright Ventures. The company plans to utilize this funding to support its growth and further develop its treatment for pulmonary embolism. Their strategy includes designing and launching new products aimed at enhancing their interventional offerings while targeting expansion into new geographic markets.

## Funding rounds

- Series A, Feb 3, 2026, $6M — Harbright Ventures

## Investors

- Harbright Ventures (https://capitalatlas.ai/funds/harbright-ventures) — Series A